Investigating how monocytes affect blood cell growth in myeloproliferative neoplasia
Official title: Exploring the Impact of Monocytes in Myeloproliferative Neoplasia
Run by University Hospital, Brest · NCT06462664 · Data updated 2026-11-12
This study is trying to see how certain immune cells called monocytes affect the growth of blood cells in people with myeloproliferative neoplasia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | University Hospital, Brest Academic / other |
| Locations | 1 site (Brest) |
| Status | Recruiting |
| Started | June 1, 2024 |
| Main results expected | January 31, 2028 |
| Study ends | January 31, 2028 |
| Registry record updated | June 17, 2024 |
| Trial ID | NCT06462664 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old who have been diagnosed with myeloproliferative neoplasia.
✕Probably not a fit
Patients who are unable to provide consent will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the role of monocytes in the growth and differentiation of hematopoietic stem cells in patients diagnosed with myeloproliferative neoplasia (MPN). By examining these cellular interactions in vitro, the study seeks to provide insights into the underlying mechanisms of MPN. Participants will be recruited from a single center, and their monocyte activity will be analyzed to understand its impact on disease progression.
Why it matters
Potential benefit: If successful, this study could lead to new therapeutic strategies targeting monocyte activity in patients with myeloproliferative neoplasia.
How similar studies have gone: While this specific approach is novel, similar studies exploring cellular interactions in hematological conditions have shown promising results.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of MPN in the participating center * Over 18 yo Exclusion Criteria: * Not able to consent
Where it's running
-
Chu Brest
Brest, France Recruiting
Study contacts
- Study coordinator: Eric LIPPERT
- Email: eric.lippert@chu-brest.fr
- Phone: 0298347033
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Caris Chromoseq data collection for AML, MDS, and MPN
This study tests how well the Caris Chromoseq assay helps categorize risk in patients with AML, MDS, or MPN compared with standard tests.
-
Using NETosis blood markers to predict clot risk in JAK2-positive myeloproliferative neoplasms
This study will try to see if blood markers of NETosis can predict clotting risk in people with JAK2V617F-positive myeloproliferative neoplasms who are at high risk for thrombosis.
-
CMV Triplex vaccine to boost immunity and prevent CMV after haploidentical stem cell transplant
This trial tests whether giving a CMV-MVA Triplex vaccine to donors and/or recipients, with or without the antiviral letermovir, can boost CMV immunity and prevent CMV viremia in people having haploidentical stem cell transplants.
-
Vedolizumab with post-transplant cyclophosphamide and short-course tacrolimus to prevent graft-versus-host disease after reduced-intensity allogeneic stem cell transplant
This trial tests whether adding vedolizumab to post-transplant cyclophosphamide and a short course of tacrolimus can prevent graft-versus-host disease in adults getting reduced-intensity allogeneic stem cell transplants for leukemias or related blood disorders.
-
Study of characteristics and complications in young patients with myeloproliferative neoplasia
This study is trying to gather information about young people under 30 with myeloproliferative neoplasia to better understand their health and complications.
-
Using Sorafenib to Prevent Relapse After Stem Cell Transplantation
This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.